secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067546
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies
--------------------------------------------------------------------------------

- Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.
- Placement agent receives up to 3.00% compensation on gross proceeds from sales.
- Terminated prior sales agreement with Jefferies under which $270.3M had been sold.
- Company not obligated to sell any shares; no assurance of any sales under new agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312526067546/0001193125-26-067546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312526067546/d259722d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer